Banzel Mobile Logo A Challenging Form of Epilepsy Seizure Types in LGS LGS Patient Profiles Pivotal Trial Design Efficacy of BANZEL® in Seizure Reduction Seizure Severity Rating Responder Rates Adverse Reactions Mechanism of Action/Pharmacokinetics Dosing

BANZEL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients 1 year of age and older, and in adults.

Prescribing Information Important Safety Information For Patients

LENNOX-GASTAUT SYNDROME (LGS) EVOLVES AS
PATIENTS AGE1

Patient boys LGS Triad
close

LGS is characterized by a triad of features4

  • Multiple seizure types
  • Slow spike-wave EEG pattern
  • Cognitive impairment

An estimated 1-4% of children diagnosed with epilepsy are thought to have LGS1-3

  • Onset usually before the age of 74
  • The syndrome may evolve as patients age1,2,4

Multiple seizure types is one of the characteristic features of LGS

LGS is characterized by triad of features4

  • Multiple seizure types
  • Slow spike-wave EEG pattern
  • Cognitive impairment
  • References: 1. Campos-Costello. Lennox-Gastaut syndrome. Orphanet Encyclopedia.
    http://www.orpha.net/data/patho/GB/uk-Lennox.pdf. Published 2003. Updated 2004. Accessed October 10, 2013. 2. Hancock et al. Treatment of Lennox-Gastaut syndrome. Cochrane Database of Systematic Review. 2013;Issue 2. 3. Trevathan et al. Prevalence and descriptive epidemiology of Lennox-Gastaut syndrome among Atlanta children. Epilepsia. 1997;38(12):1283-1288. 4. Crumrine. Lennox-Gastaut syndrome. J Child Neurol. 2002;17(suppl 1):S70-S75.
◄Previous Next: Seizure types►
Efficacy icon

EFFICACY ►

Learn about the efficacy of BANZEL® (rufinamide) in the pivotal trial